346 related articles for article (PubMed ID: 25030654)
1. Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines.
Ruiz R; Hunis B; Raez LE
Curr Oncol Rep; 2014 Sep; 16(9):400. PubMed ID: 25030654
[TBL] [Abstract][Full Text] [Related]
2. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
Reck M
Ann Oncol; 2012 Sep; 23 Suppl 8():viii28-34. PubMed ID: 22918925
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic vaccines in non-small cell lung cancer.
Socola F; Scherfenberg N; Raez LE
Immunotargets Ther; 2013; 2():115-24. PubMed ID: 27471692
[TBL] [Abstract][Full Text] [Related]
4. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy.
Rodríguez PC; Rodríguez G; González G; Lage A
MEDICC Rev; 2010; 12(1):17-23. PubMed ID: 20387330
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for lung cancer: ongoing clinical trials.
Declerck S; Vansteenkiste J
Future Oncol; 2014 Jan; 10(1):91-105. PubMed ID: 24143916
[TBL] [Abstract][Full Text] [Related]
6. CIMAvax-EGF: Toward long-term survival of advanced NSCLC.
Saavedra D; Neninger E; Rodriguez C; Viada C; Mazorra Z; Lage A; Crombet T
Semin Oncol; 2018 Jan; 45(1-2):34-40. PubMed ID: 30318082
[TBL] [Abstract][Full Text] [Related]
7. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.
Hall RD; Gray JE; Chiappori AA
Cancer Control; 2013 Jan; 20(1):22-31. PubMed ID: 23302904
[TBL] [Abstract][Full Text] [Related]
8. Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development.
Decoster L; Wauters I; Vansteenkiste JF
Ann Oncol; 2012 Jun; 23(6):1387-93. PubMed ID: 22156658
[TBL] [Abstract][Full Text] [Related]
9. Vaccination therapy for non-small-cell lung cancer.
Cuppens K; Vansteenkiste J
Curr Opin Oncol; 2014 Mar; 26(2):165-70. PubMed ID: 24441502
[TBL] [Abstract][Full Text] [Related]
10. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.
Neninger Vinageras E; de la Torre A; Osorio Rodríguez M; Catalá Ferrer M; Bravo I; Mendoza del Pino M; Abreu Abreu D; Acosta Brooks S; Rives R; del Castillo Carrillo C; González Dueñas M; Viada C; García Verdecia B; Crombet Ramos T; González Marinello G; Lage Dávila A
J Clin Oncol; 2008 Mar; 26(9):1452-8. PubMed ID: 18349395
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Antigen-specific Immunotherapy in the Treatment of Patients with Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
Yan BD; Cong XF; Zhao SS; Ren M; Liu ZL; Li Z; Chen C; Yang L
Curr Cancer Drug Targets; 2019; 19(3):199-209. PubMed ID: 29714142
[TBL] [Abstract][Full Text] [Related]
12. Current state of vaccine therapies in non-small-cell lung cancer.
Romero P
Clin Lung Cancer; 2008 Feb; 9 Suppl 1():S28-36. PubMed ID: 18540532
[TBL] [Abstract][Full Text] [Related]
13. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience.
Mellstedt H; Vansteenkiste J; Thatcher N
Lung Cancer; 2011 Jul; 73(1):11-7. PubMed ID: 21474197
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
[TBL] [Abstract][Full Text] [Related]
15. A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients.
Rodriguez PC; Popa X; Martínez O; Mendoza S; Santiesteban E; Crespo T; Amador RM; Fleytas R; Acosta SC; Otero Y; Romero GN; de la Torre A; Cala M; Arzuaga L; Vello L; Reyes D; Futiel N; Sabates T; Catala M; Flores YI; Garcia B; Viada C; Lorenzo-Luaces P; Marrero MA; Alonso L; Parra J; Aguilera N; Pomares Y; Sierra P; Rodríguez G; Mazorra Z; Lage A; Crombet T; Neninger E
Clin Cancer Res; 2016 Aug; 22(15):3782-90. PubMed ID: 26927662
[TBL] [Abstract][Full Text] [Related]
16. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.
Vansteenkiste J; Zielinski M; Linder A; Dahabreh J; Gonzalez EE; Malinowski W; Lopez-Brea M; Vanakesa T; Jassem J; Kalofonos H; Perdeus J; Bonnet R; Basko J; Janilionis R; Passlick B; Treasure T; Gillet M; Lehmann FF; Brichard VG
J Clin Oncol; 2013 Jul; 31(19):2396-403. PubMed ID: 23715567
[TBL] [Abstract][Full Text] [Related]
18. Active immunotherapy for non-small-cell lung cancer: moving toward a reality.
Perez CA; Santos ES; Raez LE
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1599-605. PubMed ID: 21999133
[TBL] [Abstract][Full Text] [Related]
19. CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine.
Tagliamento M; Rijavec E; Barletta G; Biello F; Rossi G; Grossi F; Genova C
Expert Opin Biol Ther; 2018 Jul; 18(7):829-835. PubMed ID: 29936901
[TBL] [Abstract][Full Text] [Related]
20. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.
Giaccone G; Bazhenova LA; Nemunaitis J; Tan M; Juhász E; Ramlau R; van den Heuvel MM; Lal R; Kloecker GH; Eaton KD; Chu Q; Dunlop DJ; Jain M; Garon EB; Davis CS; Carrier E; Moses SC; Shawler DL; Fakhrai H
Eur J Cancer; 2015 Nov; 51(16):2321-9. PubMed ID: 26283035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
